UA110792C2 - Лікарська форма бендамустину для перорального застосування - Google Patents

Лікарська форма бендамустину для перорального застосування

Info

Publication number
UA110792C2
UA110792C2 UAA201213173A UAA201213173A UA110792C2 UA 110792 C2 UA110792 C2 UA 110792C2 UA A201213173 A UAA201213173 A UA A201213173A UA A201213173 A UAA201213173 A UA A201213173A UA 110792 C2 UA110792 C2 UA 110792C2
Authority
UA
Ukraine
Prior art keywords
oral use
pharmaceutical form
pharmaceutically acceptable
bendamustine
form bendamustine
Prior art date
Application number
UAA201213173A
Other languages
English (en)
Inventor
Джеффрі Колледже
Марґарета Ольтофф
Original Assignee
Астеллас Дойчленд Ґмбг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Дойчленд Ґмбг filed Critical Астеллас Дойчленд Ґмбг
Priority claimed from PCT/EP2011/002764 external-priority patent/WO2011151087A1/en
Publication of UA110792C2 publication Critical patent/UA110792C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Винахід стосується фармацевтичної композиції для перорального застосування, що містить бендамустин або його фармацевтично прийнятний складний ефір, сіль або сольват у вигляді активного інгредієнта та фармацевтично прийнятний наповнювач, який є фармацевтично прийнятною неіонною гідрофільною поверхнево-активно речовиною.
UAA201213173A 2010-06-02 2011-01-06 Лікарська форма бендамустину для перорального застосування UA110792C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075231 2010-06-02
PCT/EP2011/002764 WO2011151087A1 (en) 2010-06-02 2011-06-01 Oral dosage forms of bendamustine

Publications (1)

Publication Number Publication Date
UA110792C2 true UA110792C2 (uk) 2016-02-25

Family

ID=42651316

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201213173A UA110792C2 (uk) 2010-06-02 2011-01-06 Лікарська форма бендамустину для перорального застосування

Country Status (1)

Country Link
UA (1) UA110792C2 (uk)

Similar Documents

Publication Publication Date Title
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX348823B (es) Formulaciones estables de linaclotida.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
TN2015000135A1 (en) Modified release formulations for oprozomib
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
TR201803451T4 (tr) Olmesartan formülasyonlari.
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
IN2014CN04119A (uk)
IN2012CH05549A (uk)
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора